Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Adjunctive Aripiprazole in Bipolar Depression
NCT01520350Phase 3Terminated
- Start
- Feb 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Mood stabilizer + Aripiprazole with Mood stabilizer + placebo (2 arms). Primary endpoint: Response rate at 8 weeks. Started Feb 2012; status: terminated.
02
Drugs
aripiprazole
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT01520350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01520350.